Asian Liver Center

Last updated

The Asian Liver Center is a non-profit organization at Stanford University, United States, that researches the high incidence of hepatitis B and liver cancer in Asians and Asian Americans. The Asian Liver Center (ALC) was founded in 1996 to spearhead educational outreach and advocacy efforts in the areas of hepatitis B and liver cancer prevention and treatment, serves as a resource for both the general public and health practitioners, and implements clinical and research programs.

Contents

History

The Asian Liver Center was founded in 1996 by Dr. Samuel So. Since its establishment in 1996, ALC has become a national and international leader in the fight against hepatitis B and liver cancer. It uses the help of a network of governmental and nongovernmental agencies, state and federal legislators, private corporations and foundations, and community partners.

Outreach and education

The key to winning the fight against hepatitis B and liver cancer is prevention, and prevention begins with outreach and education. The Asian Liver Center is dedicated to serving the Asian community through a variety of outreach and education programs. A HBV safe and effective vaccine is available, offering protection from the hepatitis B virus (HBV), but many API are not vaccinated because they are not aware of the problem and its prevalence in their community.

ALC participates in community events throughout the Bay Area, providing screenings and low-cost vaccinations, hosting educational booths and games, speaking to health care providers and developing workshops to spread awareness about hepatitis B and liver cancer. The outreach section of the ALC website gives details of screenings, conferences, community events, advocacy efforts, partnerships, ongoing projects, and contests. The education section of the site includes information about hepatitis B, liver cancer, vaccination and blood tests as well as patient testimonials and resources for health care providers.

Advocacy

ALC supports the expansion of the Jade Ribbon Campaign. In California, the Asian Liver Center is working with Assemblywoman Fiona Ma to pass Assembly Bill 158, which will provide care for all uninsured and under-insured people who are chronically infected with hepatitis B, with no raise in taxes. Nationally, the Asian Liver Center worked with Congressman Mike Honda co-sponsored a bill early in 2006 to designate the first National Hepatitis B Awareness Week in May 2006. In April 2004, the Jade Ribbon Campaign was launched by the ALC in China in partnership with the China Foundation for Hepatitis Prevention and Control at the China National Hepatitis Conference. The Asian Liver Center advocates for laws that prevent hepatitis B discrimination, strategies to provide access to affordable screenings, vaccinations and treatment, and partnerships to unite against HBV and liver cancer.

Research

Research in liver cancer has generally received low priority for federal funding in this country, contributing to the lack of effective treatment for chronically infected individuals. The ALC research program is looking for novel approaches to increase the efficacy of diagnosis, prognosis, and treatment through the development of a liver cancer research program with an emphasis on liver cancer genomics, biomarkers, molecular targets, and investigational anti-tumor agents.

ALC is working on a perinatal hepatitis B prevention initiative to design and implement strategies to prevent mother-to-child transmission of hepatitis B in Alameda and Santa Clara counties, where the combined population of about 3.2 million experiences some of the highest rates of chronic HBV and liver cancer in the US.

Jade Ribbon campaign

The Jade Ribbon Campaign (JRC) was launched by the Asian Liver Center (ALC) at Stanford University in May 2001 during Asian Pacific American Heritage Month to help spread awareness internationally about hepatitis B (HBV) and liver cancer in Asian and Pacific Islander (API) communities. [1] [2]

The objective of the Jade Ribbon Campaign is to eradicate HBV worldwide; and to reduce the incidence and mortality associated with liver cancer. Considered to be the essence of heaven and earth, Jade is believed in many Asian cultures to bring good luck and longevity while deflecting negativity. Folded like the Chinese character “人” (ren) meaning "person" or "people," the Jade Ribbon symbolizes the spirit of the campaign in bringing the Asian and global community together to combat the epidemic.

Since the campaign's founding, the Asian Liver Center (ALC) has been spearheading the Jade Ribbon Campaign through public service announcements in media such as newspapers, magazines, TV, radio, billboard, and buses targeting communities with large API populations. The ALC holds seminars for health professionals and the public, cultural fairs, conferences, and HBV screening/vaccination events. [2]

Related Research Articles

<span class="mw-page-title-main">Hepatitis</span> Inflammation of the liver

Hepatitis is inflammation of the liver tissue. Some people or animals with hepatitis have no symptoms, whereas others develop yellow discoloration of the skin and whites of the eyes (jaundice), poor appetite, vomiting, tiredness, abdominal pain, and diarrhea. Hepatitis is acute if it resolves within six months, and chronic if it lasts longer than six months. Acute hepatitis can resolve on its own, progress to chronic hepatitis, or (rarely) result in acute liver failure. Chronic hepatitis may progress to scarring of the liver (cirrhosis), liver failure, and liver cancer.

<span class="mw-page-title-main">Hepatitis C</span> Human viral infection

Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver; it is a type of viral hepatitis. During the initial infection period, people often have mild or no symptoms. Early symptoms can include fever, dark urine, abdominal pain, and yellow tinged skin. The virus persists in the liver, becoming chronic, in about 70% of those initially infected. Early on, chronic infection typically has no symptoms. Over many years however, it often leads to liver disease and occasionally cirrhosis. In some cases, those with cirrhosis will develop serious complications such as liver failure, liver cancer, or dilated blood vessels in the esophagus and stomach.

<span class="mw-page-title-main">Hepatocellular carcinoma</span> Medical condition

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults and is currently the most common cause of death in people with cirrhosis. HCC is the third leading cause of cancer-related deaths worldwide.

<span class="mw-page-title-main">Viral hepatitis</span> Liver inflammation from a viral infection

Viral hepatitis is liver inflammation due to a viral infection. It may present in acute form as a recent infection with relatively rapid onset, or in chronic form.

<span class="mw-page-title-main">Lamivudine</span> Chemical compound

Lamivudine, commonly called 3TC, is an antiretroviral medication used to prevent and treat HIV/AIDS. It is also used to treat chronic hepatitis B when other options are not possible. It is effective against both HIV-1 and HIV-2. It is typically used in combination with other antiretrovirals such as zidovudine and abacavir. Lamivudine may be included as part of post-exposure prevention in those who have been potentially exposed to HIV. Lamivudine is taken by mouth as a liquid or tablet.

The Jade Ribbon Campaign (JRC) also known as JoinJade, was launched by the Asian Liver Center (ALC) at Stanford University in May 2001 during Asian Pacific American Heritage Month to help spread awareness internationally about hepatitis B (HBV) and liver cancer in Asian and Pacific Islander (API) communities.

Hepatitis B is endemic in China. Of the 350 million individuals worldwide infected with the hepatitis B virus (HBV), one-third reside in China. As of 2006 China has immunized 11.1 million children in its poorest provinces as part of several programs initiated by the Chinese government and as part of the Global Alliance for Vaccines and Immunization (GAVI). However, the effects of these programs have yet to reach levels of immunization that would limit the spread of hepatitis B effectively.

<span class="mw-page-title-main">Liver cancer</span> Medical condition

Liver cancer is cancer that starts in the liver. Liver cancer can be primary or secondary. Liver metastasis is more common than that which starts in the liver. Liver cancer is increasing globally.

<span class="mw-page-title-main">Hepatitis B vaccine</span> Vaccine against hepatitis B

Hepatitis B vaccine is a vaccine that prevents hepatitis B. The first dose is recommended within 24 hours of birth with either two or three more doses given after that. This includes those with poor immune function such as from HIV/AIDS and those born premature. It is also recommended that health-care workers be vaccinated. In healthy people, routine immunization results in more than 95% of people being protected.

San Francisco Hep B Free is a citywide campaign to turn San Francisco into the first hepatitis B free city in the United States. This unprecedented campaign began in 2007, with the objective to screen, vaccinate, and treat all San Francisco Asian and Pacific Islander (API) residents for hepatitis B by providing convenient, free or low-cost testing opportunities at partnering health facilities and events.

<span class="mw-page-title-main">Hepatitis B</span> Human viral infection

Hepatitis B is an infectious disease caused by the Hepatitis B virus (HBV) that affects the liver; it is a type of viral hepatitis. It can cause both acute and chronic infection.

LIVERight is the first 5K run/walk to raise awareness about hepatitis B and liver cancer. The goal of LIVERight was not only to raise money for outreach efforts, but more importantly to educate and increase awareness of this pressing public health issue. Educational displays, informational booths and of course signs were unique and significant components to the event. The education allowed participants to learn more about hepatitis B prevention and treatment, as well as hear the real stories about the lives lost and won to liver cancer.

<span class="mw-page-title-main">World Hepatitis Day</span> WHO public health campaign

World Hepatitis Day, observed on July 28 every year, aims to raise global awareness of hepatitis — a group of infectious diseases known as hepatitis A, B, C, D, and E — and encourage prevention, diagnosis and treatment. Hepatitis affects hundreds of millions of people worldwide, causing acute and chronic disease and killing close to 1.34 million people every year. Hepatitis can cause inflammation of the liver both acutely and chronically, and can kill a person. In some countries hepatitis B is the most common cause of cirrhosis and may also cause liver cancer.

<span class="mw-page-title-main">2009 Gujarat hepatitis outbreak</span>

The 2009 Gujarat hepatitis B outbreak was a cluster of hepatitis B cases that appeared in Modasa, northern Gujarat, India in 2009. Over 125 people were infected and up to 49 people died. Several doctors were investigated and arrested after the outbreaks.

Asian Americans have historically been perceived as a "model minority," experiencing few health problems relative to other minority groups. Research within the past 20 years, however, has shown that Asian Americans are at high risk for hepatitis B, liver cancer, tuberculosis, and lung cancer, among other conditions. Asian American health disparities have only gained focus in the past 10 years, with policy initiatives geared towards promoting healthcare access to Asian Americans rising to prominence even later. Asian Americans are defined as Americans of Asian ancestry and constitute nearly 5% of American's population as of 2003, according to the U.S. Census Bureau. Yet, the Asian American population can hardly be described as homogenous. The term applies to members of over 25 groups that have been classified as a single group because of similar appearances, cultural values, and common ethnic backgrounds. The Asian Americans commonly studied have been limited primarily to individuals of Cambodian, Chinese, Filipino, Hmong, Japanese, Korean, Lao, Mien, or Vietnamese descent.

Robert Palmer Beasley was a physician, public health educator and epidemiologist whose work on hepatitis B involved extensive investigations in Taiwan. That work established that hepatitis B virus (HBV) is a primary cause of liver cancer and that hepatitis B virus is transmitted from mother to infant during childbirth. Beasley and his colleagues also proved that HBV mother-to-infant transmission is preventable by at-birth vaccination. Due to this work, the World Health Assembly designated HBV as the seventh global vaccine in 1992. He later became the author of HBV immunization policies for the World Health Organization.

Infectious diseases within American correctional settings are a concern within the public health sector. The corrections population is susceptible to infectious diseases through exposure to blood and other bodily fluids, drug injection, poor health care, prison overcrowding, demographics, security issues, lack of community support for rehabilitation programs, and high-risk behaviors. The spread of infectious diseases, such as HIV and other sexually transmitted diseases, hepatitis C (HCV), hepatitis B (HBV), and tuberculosis, result largely from needle-sharing, drug use, and consensual and non-consensual sex among prisoners. HIV and hepatitis C need specific attention because of the specific public health concerns and issues they raise.

Shiv Kumar Sarin is an Indian gastroenterologist, hepatologist, translational scientist, researcher and teacher. He set up the Institute of Liver and Biliary Sciences. He is a recipient of the Shanti Swarup Bhatnagar Prize and the Padma Bhushan. He served as Chairman of the Board of Governors of Medical Council of India. He was the president of the Asian Pacific Association for the Study of the Liver and founder of Asian Pacific School of Hepatology.

The Hepatitis B Foundation (HBF) is an American nonprofit organization dedicated to finding a cure for hepatitis B and improving the lives of those already affected by the disease. Established in 1991, the foundation's headquarters is in Doylestown, PA. It is the only non-profit in the United States focused solely on hepatitis B. The foundation conducts biomedical research, promotes disease awareness, and acts as an information source for patients, the medical community, and the general public. The Hepatitis B Foundation's research arm, the Baruch S. Blumberg Institute, has the largest number of non-profit scientists dedicated to hepatitis B research in the world. The organization also leads national public policy initiatives and international public health programs.

George Lau is a specialist in gastroenterology and hepatology, currently the founder and chairman of the Humanity and Health Medical Group in Hong Kong.

References

  1. ↑ The Jade Ribbon Campaign. "Jade Ribbon Campaign - Outreach - Asian Liver Center - Stanford University School of Medicine - Unite against hepatitis B & liver cancer!". Archived from the original on 2009-10-08. Retrieved 2009-08-24.
  2. 1 2 Chao, S. D.; Chang, E. T.; Le, P. V.; Prapong, W; Kiernan, M; So, S. K. (2009). "The Jade Ribbon Campaign: A model program for community outreach and education to prevent liver cancer in Asian Americans". Journal of Immigrant and Minority Health . 11 (4): 281–90. doi:10.1007/s10903-007-9094-2. PMID   17990118. S2CID   23813176.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.